Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Lomas, E. Silverman, L. Edwards, N. Locantore, B. Miller, D. Horstman, R. Tal-Singer, On Behalf of the ECLIPSE Study Investigators (SCO104960; NCT00292552; NCT00379730) (Cambridge, United Kingdom; Boston, MA, Research Triangle Park, NC, King of Prussi. Serum surfactant protein D (SP-D) is a lung derived biomarker for COPD that is responsive to treatment with oral corticosteroids. Eur Respir J 2008; 32: Suppl. 52, 3108

Member's Comments

Lars Gronke - 07.10.2008 11:22
Statistical significance vs. usefulness
Isn`t the huge overlap between the treatment groups impacting the clinical usefulness of the marker, despite the p-value ?

Related content which might interest you: Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Serum Surfactant Protein D is decreased by oral steroids in asthma but not COPD Source: International Congress 2018 – Clinical determinants of asthma and biomarkers Year: 2018 Serum surfactant protein D (SPD) as a specific marker for COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Surfactant protein D as a potential serum marker of pulmonary emphysema Source: Annual Congress 2011 - Smoking-related disorders and smoking prevention Year: 2011 Change in serum surfactant protein (SP)-A, SP-D and KL-6 predict the therapeutic effect of antifibrotic drugs in IPF. Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD Source: Eur Respir J 2009; 34: 95-102 Year: 2009 COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015 Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 The relationhip between serum levels of Surfactant protein D in COPD exacerbation severity and mortality Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Early stage asymptomatic (HRCT detectable) patients with IPF showed augmented serum surfactant protein D (SP-D) Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002 Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Asthmatics with high levels of serum surfactant protein D have more severe disease Source: Eur Respir J 2016; 47:1864-1867 Year: 2016 Plasma biomarkers and response to therapy at exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 39s Year: 2007 Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017